Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or...

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomedical Engineering

Background:

• Abciximab infusion and uncoated stents are standard for ST-segment elevation myocardial infarction (STEMI) angioplasty.
• Uncertainty exists regarding tirofiban's efficacy versus abciximab and the role of drug-eluting stents in STEMI.
• Previous studies reported conflicting results on drug-eluting stent efficacy and safety in STEMI patients.

Purpose of the Study:

• To compare high-dose bolus tirofiban with abciximab infusion in STEMI patients undergoing percutaneous coronary intervention.
• To evaluate the efficacy of sirolimus-eluting stents versus uncoated stents in STEMI patients.
• To assess major adverse cardiac events (MACE) and ST-segment resolution in STEMI patients.

Main Methods:

• An open-label, 2x2 factorial trial involving 745 STEMI patients across 16 centers.
• Patients received either high-dose bolus tirofiban or abciximab infusion.
• Sirolimus-eluting stents were compared against uncoated stents.

Main Results:

• Tirofiban demonstrated noninferior ST-segment resolution (85.3%) compared to abciximab (83.6%).
• Ischemic and hemorrhagic outcomes were similar between tirofiban and abciximab groups.
• Sirolimus-eluting stents reduced MACE by 46% (7.8% vs 14.5%) compared to uncoated stents at 8 months, primarily due to lower revascularization rates.

Conclusions:

• High-dose bolus tirofiban is a viable alternative to abciximab infusion for STEMI patients.
• Sirolimus-eluting stents significantly improve outcomes in STEMI patients undergoing percutaneous coronary intervention.
• The study supports the use of sirolimus-eluting stents in STEMI patients to reduce major adverse cardiac events.